Skip to main content
European Commission logo print header

Pharmacodynamic Approaches to Demonstration of Disease-Modification in Huntington’s Disease by SEN0014196

Objective

The Consortium will undertake clinical research activities aimed at ascertaining feasibility of a range of pharmacodynamic readouts for use in the clinical development of SEN0014196 to demonstrate the disease-modifying properties of the compound in Huntington’s Disease. SEN0014196 is a novel and selective SirT1 inhibitor, currently in Phase I clinical development, and enjoys Orphan Status in the EU as of September 2, 2009. A multi-factorial approach will be used, including assessment of both novel and compound-specific measures of molecular action as well as previously identified predictors of disease progression. The translational approaches addressed by this project are instrumental in the progression of SEN0014196 to clinical proof-of-concept and, if successful, will play a pivotal role in patient stratification and outcomes research. The Consortium will comprise four partners, all with a proven track-record in Research and Development in the Huntington’s Disease area. All Partners are based within the EU.

Call for proposal

FP7-HEALTH-2010-single-stage
See other projects for this call

Coordinator

SIENA BIOTECH SPA
EU contribution
€ 1 540 673,73
Address
Via Banchi di Sotto 34
53100 SIENA
Italy

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Enrica Diodato (Dr.)
Links
Total cost
No data

Participants (4)